Oral Administration of MBG to Modulate Immune Responses and Suppress OVA-Sensitized Allergy in a Murine Model

Table 1

The expression levels of surface markers on mice splenocytes from B6 mice treated with MBG in different dosages.

Surface markers	Control	Treatment mice
		PC	Low	Med.	High
CD3 (%)	24.96±3.3	28.01±0.9^∗	27.94±2.1^∗	28.32±2.5^∗	28.46±0.8^∗
CD4 (%)	16.36±2.4	21.27±0.9^∗	24.85±4.4^∗	20.03±1.9^∗	20.12±1.5^∗
CD8 (%)	7.73±1.8	8.81±0.5^∗	9.38±1.5^∗	8.33±1.0^∗	9.19±1.5^∗
CD22 (%)	52.95±6.5	51.18±0.7	50.19±4.6	52.12±4.9	51.42±1.1
F4/80 (%)	91.00±4.0	99.61±0.1^∗	90.92±1.7	99.74±0.2^∗	99.59±0.1^∗

∗Significant difference at 𝑃<0.05 level compared with those of control. The values shown in the flow cytometry profiles are the mean fluorescence intensity (MFI) indices. Each value represents the mean ± SD from ten independent experiments. Statistical significance is indicated by 𝑃 values (Duncan’s test).